Novartis AG (NVS) Stock Price & Analysis
Score
AI Analysis
SnapshotNovartis AG doesn’t screen as a clean setup today — Stocklytics 39/100 leaves more to prove. Under the hood: P/E 31.6, rich vs its own history, plus revenue compounding ~8% annually over recent years.
Price History
Price: —
Fair value: —
—
P/E (TTM): —
Net Income (TTM): —
Score: —
—
Score Breakdown
Market percentile scores loading…
Value
Growth
Quality
Financial Summary
Novartis AG (NVS) last printed $159.33. Equity value is $300.91B. Trailing earnings multiple 30.44. The revenue row is reported history. Targets and ratings are on the forecast page.
Financials
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|
| $49.44B | $43.4B | $46.1B | $48.68B | $49.9B | $43.97B | $43.46B | $46.66B | $51.72B | $54.81B |
About
Novartis AG is a holding company, which engages in the business of developing, manufacturing, and marketing healthcare products. Its product portfolio is heavily focused on innovative prescription medicines, especially oncology, immunology, neuroscience, and cardiovascular diseases, supplemented by established older brands and a wide range of specialized therapies. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland.